The field of immuno-oncology is transforming cancer care at an unprecedented pace. From next-generation cell therapies and antibody-drug conjugates (ADCs) to biomarker-driven precision medicine and AI-powered diagnostics, groundbreaking discoveries are reshaping how cancer is diagnosed, treated, and monitored.
For researchers, clinicians, pharmaceutical professionals, biotech innovators, and healthcare executives, attending an immuno-oncology conference is one of the most effective ways to stay ahead of these advancements. If you’re planning your professional development in 2026, the United States offers one of the world’s most dynamic environments for cancer research, clinical innovation, and industry collaboration.
Why Attend the 2nd Immuno-Oncology & Biomarker Summit 2026?
Scheduled for 19–20 October 2026 in Philadelphia, USA, the 2nd Immuno-Oncology & Biomarker Summit 2026 will bring together senior decision-makers from pharmaceutical companies, biotechnology firms, academia, diagnostics, and clinical research organizations. The summit focuses on practical, real-world applications of immuno-oncology and biomarker science through keynote presentations, panel discussions, technical sessions, and dedicated networking opportunities. Topics include advanced immunotherapies, precision oncology, translational research, companion diagnostics, clinical trials, and AI-enabled biomarker strategies.
Register Early and Plan Your Travel
International delegates are encouraged to register early to secure their place and take advantage of available travel and accommodation options.
Planning ahead allows attendees to:
- Secure early registration
- Book convenient hotel accommodations
- Arrange international travel
- Schedule networking meetings in advance
- Maximize participation in scientific and business sessions
Whether you’re a researcher, clinician, biotech innovator, pharmaceutical executive, or healthcare professional, attending an immuno-oncology conference in the USA provides an unparalleled opportunity to learn from global experts, discover breakthrough research, and build partnerships that accelerate the future of cancer treatment.
Whether you’re attending to learn, network, or showcase your solutions, now is the perfect time to secure your participation. Register as a delegate or become a sponsor to engage with the global immuno-oncology community.
Experience the USA’s Leadership in Biotech and Immuno-Oncology
The United States continues to lead the global biotechnology and life sciences industry, making it the ideal destination for immuno-oncology conferences. Renowned innovation hubs such as Boston, Philadelphia, San Diego, and the San Francisco Bay Area are home to leading pharmaceutical companies, biotechnology startups, academic medical centers, and world-class cancer research institutions.
These ecosystems drive innovation in:
- Cancer immunotherapy
- Precision oncology
- Biomarker discovery
- Companion diagnostics
- Cell and gene therapies
- Artificial intelligence in oncology
Philadelphia, the host city for the 2nd Immuno-Oncology & Biomarker Summit 2026, has emerged as one of the fastest-growing life sciences hubs in the United States. The city offers access to cutting-edge research institutions, biotechnology companies, healthcare systems, and a thriving innovation ecosystem that fosters scientific collaboration and translational research.
Gain Insights into the Latest Clinical Trials and Research
One of the greatest advantages of attending an immuno-oncology conference in the USA is direct access to the latest clinical research and emerging therapeutic strategies.
Leading scientists and industry experts present new findings from ongoing and completed clinical trials, providing attendees with valuable insights into:
- Next-generation checkpoint inhibitors
- CAR-T and TCR cell therapies
- Bispecific antibodies
- Antibody-drug conjugates (ADCs)
- mRNA cancer vaccines
- Tumor microenvironment research
- Novel immune targets
- Combination immunotherapy strategies
The 2nd Immuno-Oncology & Biomarker Summit 2026 also highlights advances in biomarker-driven precision medicine, including liquid biopsy, measurable residual disease (MRD), spatial biology, AI-driven imaging biomarkers, and multi-omics integration. These innovations are helping clinicians improve patient selection, optimize treatment decisions, and accelerate personalized cancer care.
Learn How Biomarkers Are Shaping Precision Oncology
Modern immuno-oncology increasingly depends on biomarkers to identify the right treatment for the right patient.
Conference sessions dedicated to biomarker science allow attendees to explore:
- Companion diagnostics (CDx)
- Predictive and prognostic biomarkers
- Clinical trial optimization
- Biomarker validation
- Regulatory considerations
- Real-world evidence
- AI-enabled biomarker discovery
Understanding how biomarkers influence immunotherapy development can help researchers and pharmaceutical companies improve clinical outcomes while reducing development timelines.
Build Valuable Connections Across Pharma and Biotech
Scientific knowledge is only one part of the conference experience. Equally important are the networking opportunities available throughout the event.
An immuno-oncology conference in the USA brings together professionals from across the healthcare ecosystem, including:
- Global pharmaceutical companies
- Biotechnology organizations
- Clinical research organizations (CROs)
- Academic institutions
- Diagnostic developers
- Regulatory experts
- Investors and venture capital firms
- Healthcare providers
These interactions often lead to research collaborations, licensing opportunities, strategic partnerships, recruitment, and future clinical trial initiatives.
Whether you’re seeking collaborators for translational research or exploring commercial partnerships, face-to-face networking remains one of the most valuable aspects of attending industry conferences.
Join the 2nd Immuno-Oncology & Biomarker Summit 2026 in Philadelphia and become part of the conversations driving the next generation of precision oncology and cancer immunotherapy.
